Walleye Capital’s Achieve Life Sciences ACHV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-82,599
Closed -$340K 5364
2023
Q4
$340K Buy
82,599
+12,940
+19% +$56.4K ﹤0.01% 3269
2023
Q3
$300K Sell
69,659
-25,374
-27% -$128K ﹤0.01% 3239
2023
Q2
$493K Buy
95,033
+69,960
+279% +$491K ﹤0.01% 2455
2023
Q1
$170K Buy
+25,073
New +$119K ﹤0.01% 2589
2021
Q3
Sell
-27,307
Closed -$245 1565
2021
Q2
$245 Buy
+27,307
New +$260K 0.01% 1008
2018
Q3
$43K Buy
+684
New +$43.3K 0.02% 290

Other funds holding ACHV

Walleye Capital's ACHV Position: Q1 2024 in Review

Walleye Capital sold out of Achieve Life Sciences (ACHV) in Q1 2024, closing a stake of 82,599 shares — an estimated $340K sold.

Walleye Capital first reported a position in ACHV in Q3 2018 and held it in 6 quarters. The position peaked at $493K in Q2 2023. 41 funds tracked by Wall St. Rank hold ACHV as of Q1 2024.

  • Walleye Capital reported no remaining Achieve Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 82,599 Achieve Life Sciences shares in Q1 2024, an estimated $340K.
  • Walleye Capital first reported a position in Achieve Life Sciences in Q3 2018 and held it in 6 quarters.
  • Walleye Capital's Achieve Life Sciences position peaked at $493K in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.